A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Trial Profile

A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Nitric oxide (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions
  • Sponsors Novan Inc
  • Most Recent Events

    • 05 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 May 2018.
    • 05 Dec 2017 According to a Novan media release, first patient has been dosed in the trial. Top line results are targeted for the third quarter of 2018.
    • 05 Dec 2017 Status changed from planning to recruiting, according to a Novan media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top